Effects of ranibizumab and aflibercept on human Müller cells and photoreceptors under stress conditions

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  Shen, Weiyong ^a   Yau, Belinda ^a   Lee, So Ra ^a   Zhu, Ling ^a   Yam, Michelle ^a   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aflibercept; Heat shock proteins; Interphotoreceptor retinoid binding protein; M ller cells; Neurotrophic factors; Photoreceptors; Ranibizumab; Redox proteins; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; CHAPERONIN 60; GLUCOSE; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; RANIBIZUMAB; THIOREDOXIN 1; THIOREDOXIN 2; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; EYE PROTEIN; HEAT SHOCK PROTEIN; HYBRID PROTEIN; INTERSTITIAL RETINOL-BINDING PROTEIN; NERVE GROWTH FACTOR; RETINOL BINDING PROTEIN; THIOREDOXIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CALCEIN-AM ASSAY; CELL SURVIVAL; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPOXIA; MUELLER CELL; PHOTORECEPTOR; PHOTORECEPTOR CELL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STARVATION; STRESS; VASCULAR DISEASE; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; MACROGLIA; METABOLISM; PHYSIOLOGICAL STRESS;

ANGIOGENESIS INHIBITORS; CELL SURVIVAL; CELLS, CULTURED; EPENDYMOGLIAL CELLS; EYE PROTEINS; GENE EXPRESSION; GLUCOSE; HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA; NERVE GROWTH FACTORS; PHOTORECEPTOR CELLS; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINOL-BINDING PROTEINS; STRESS, PHYSIOLOGICAL; THIOREDOXINS;

EID: 85014629770     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030533     Document Type: Article

References (59)

1. Miller, J.W.; Le Couter, J.; Strauss, E.C.; Ferrara, N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013, 120, 106–114.
2. Sene, A.; Chin-Yee, D.; Apte, R.S. Seeing through VEGF: Innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol. Med. 2015, 21, 43–51.
3. Jager, R.D.; Mieler, W.F.; Miller, J.W. Age-related macular degeneration. N. Engl. J. Med. 2008, 358, 2606–2617.
4. Antonetti, D.A.; Klein, R.; Gardner, T.W. Diabetic retinopathy. N. Engl. J. Med. 2012, 366, 1227–1239.
5. Semeraro, F.; Morescalchi, F.; Duse, S.; Parmeggiani, F.; Gambicorti, E.; Costagliola, C. Aflibercept in wet AMD: Specific role and optimal use. Drug Des. Dev. Ther. 2013, 7, 711–722.
6. Saint-Geniez, M.; Kurihara, T.; Sekiyama, E.; Maldonado, A.E.; D’Amore, P.A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl. Acad. Sci. USA 2009, 106, 18751–18756.
7. Marneros, A.G.; Fan, J.; Yokoyama, Y.; Gerber, H.P.; Ferrara, N.; Crouch, R.K.; Olsen, B.R. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 2005, 167, 1451–1459.
8. Byeon, S.H.; Lee, S.C.; Choi, S.H.; Lee, H.K.; Lee, J.H.; Chu, Y.K.; Kwon, O.W. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Investig. Ophthalmoil Vis. Sci. 2010, 51, 1190–1197.
9. Foxton, R.H.; Finkelstein, A.; Vijay, S.; Dahlmann-Noor, A.; Khaw, P.T.; Morgan, J.E.; Shima, D.T.; Ng, Y.S. VEGF-A Is Necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am. J. Pathol. 2013, 182, 1379–1390.
10. Brar, V.S.; Sharma, R.K.; Murthy, R.K.; Chalam, K.V. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol. Vis. 2010, 16, 1848–1853.
11. Hombrebueno, J.R.; Ali, I.H.; Xu, H.; Chen, M. Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2(Akita) diabetic mouse. Sci. Rep. 2015, 5, 18316.
12. Park, H.Y.; Kim, J.H.; Park, C.K. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am. J. Pathol. 2014, 184, 1752–1762.
13. Saint-Geniez, M.; Maharaj, A.S.; Walshe, T.E.; Tucker, B.A.; Sekiyama, E.; Kurihara, T.; Darland, D.C.; Young, M.J.; D'Amore, P.A. Endogenous VEGF is required for visual function: Evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 2008, 3, e3554.
14. Kurihara, T.; Westenskow, P.D.; Bravo, S.; Aguilar, E.; Friedlander, M. Targeted deletion of Vegfa in adult mice induces vision loss. J. Clin. Investig. 2012, 122, 4213–4217.
15. Bringmann, A.; Pannicke, T.; Grosche, J.; Francke, M.; Wiedemann, P.; Skatchkov, S.N.; Osborne, N.N.; Reichenbach, A. Müller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 2006, 25, 397–424.
16. Yang, X.M.; Yafai, Y.; Wiedemann, P.; Kuhrt, H.; Wang, Y.S.; Reichenbach, A.; Eichler, W. Hypoxia-induced upregulation of pigment epithelium-derived factor by retinal glial (Müller) cells. J. Neurosci. Res. 2012, 90, 257–266.
17. Unterlauft, J.D.; Eichler, W.; Kuhne, K.; Yang, X.M.; Yafai, Y.; Wiedemann, P.; Reichenbach, A.; Claudepierre, T. Pigment epithelium-derived factor released by Müller glial cells exerts neuroprotective effects on retinal ganglion cells. Neurochem. Res. 2012, 37, 1524–1533.
18. Shen, W.; Zhu, L.; Lee, S.R.; Chung, S.H.; Gillies, M.C. Involvement of NT3 and P75(NTR) in photoreceptor degeneration following selective Müller cell ablation. J. Neuroinflam. 2013, 10, 137.
19. Vogler, S.; Hollborn, M.; Berk, B.A.; Pannicke, T.; Seeger, J.; Wiedemann, P.; Reichenbach, A.; Bringmann, A. Ischemic regulation of brain-derived neurotrophic factor-mediated cell volume and TrkB expression in glial (Müller) and bipolar cells of the rat retina. Graefes Arch. Clin. Exp. Ophthalmol. 2016, 254, 497–503.
20. Malik, D.; Tarek, M.; Caceres del Carpio, J.; Ramirez, C.; Boyer, D.; Kenney, M.C.; Kuppermann, B.D. Safety profiles of anti-VEGF drugs: Bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br. J. Ophthalmol. 2014, 98 (Suppl. 1), i11–i16.
21. Klettner, A.; Mohle, F.; Roider, J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248, 819–824.
22. Peng, S.; Adelman, R.A.; Rizzolo, L.J. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions. Investig. Ophthalmol. Vis. Sci. 2010, 51, 3216–3225.
23. Schnichels, S.; Hagemann, U.; Januschowski, K.; Hofmann, J.; Bartz-Schmidt, K.U.; Szurman, P.; Spitzer, M.S.; Aisenbrey, S. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br. J. Ophthalmol. 2013, 97, 917–923.
24. Salminen, A.; Ojala, J.; Kaarniranta, K.; Hiltunen, M.; Soininen, H. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Prog. Neurobiol. 2011, 93, 99–110.
25. Bross, P.; Magnoni, R.; Bie, A.S. Molecular chaperone disorders: Defective Hsp60 in neurodegeneration. Curr. Top. Med. Chem. 2012, 12, 2491–2503.
26. Vlamis-Gardikas, A.; Holmgren, A. Thioredoxin and glutaredoxin isoforms. Methods Enzymol. 2002, 347, 286–296.
27. Seigel, G.M.; Notter, M.F. Differentiation of Y79 retinoblastoma cells induced by succinylated concanavalin A. Cell Growth Differ. 1993, 4, 1–7.
28. Rehemtulla, A.; Warwar, R.; Kumar, R.; Ji, X.; Zack, D.J.; Swaroop, A. The basic motif-leucine zipper transcription factor Nrl can positively regulate rhodopsin gene expression. Proc. Natl. Acad. Sci. USA 1996, 93, 191–195.
29. Craft, C.M.; Xu, J.; Slepak, V.Z.; Zhan-Poe, X.; Zhu, X.; Brown, B.; Lolley, R.N. PhLPs and PhLOPs in the phosducin family of Gβγ binding proteins. Biochemistry 1998, 37, 15758–15772.
30. Li, A.; Zhu, X.; Craft, C.M. Retinoic acid upregulates cone arrestin expression in retinoblastoma cells through a Cis element in the distal promoter region. Investig. Ophthalmol. Vis. Sci. 2002, 43, 1375–1383.
31. Garcia-Ramirez, M.; Hernandez, C.; Villarroel, M.; Canals, F.; Alonso, M.A.; Fortuny, R.; Masmiquel, L.; Navarro, A.; Garcia-Arumi, J.; Simo, R. Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 2009, 52, 2633–2641.
32. Ozaki, H.; Yu, A.Y.; Della, N.; Ozaki, K.; Luna, J.D.; Yamada, H.; Hackett, S.F.; Okamoto, N.; Zack, D.J.; Semenza, G.L. et al. Hypoxia inducible factor-1α is increased in ischemic retina: Temporal and spatial correlation with VEGF expression. Investig. Ophthalmol. Vis. Sci. 1999, 40, 182–189.
33. Bai, Y.; Ma, J.X.; Guo, J.; Wang, J.; Zhu, M.; Chen, Y.; Le, Y.Z. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J. Pathol. 2009, 219, 446–454.
34. Kvanta, A.; Steen, B.; Seregard, S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp. Eye Res. 1996, 63, 511–518.
35. De Gooyer, T.E.; Stevenson, K.A.; Humphries, P.; Simpson, D.A.; Gardiner, T.A.; Stitt, A.W. Retinopathy is reduced during experimental diabetes in a mouse model of outer retinal degeneration. Investig. Ophthalmol. Vis. Sci. 2006, 47, 5561–5568.
36. Arden, G.B.; Sidman, R.L.; Arap, W.; Schlingemann, R.O. Spare the rod and spoil the eye. Br. J. Ophthalmol. 2005, 89, 764–769.
37. Arden, G.B. The absence of diabetic retinopathy in patients with retinitis pigmentosa: Implications for pathophysiology and possible treatment. Br. J. Ophthalmol. 2001, 85, 366–370.
38. Du, Y.; Veenstra, A.; Palczewski, K.; Kern, T.S. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc. Natl. Acad. Sci. USA 2013, 110, 16586–16591.
39. Joyal, J.S.; Sun, Y.; Gantner, M.L.; Shao, Z.; Evans, L.P.; Saba, N.; Fredrick, T.; Burnim, S.; Kim, J.S.; Patel, G. et al. Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1. Nat. Med. 2016, 22, 439–445.
40. Puddu, A.; Sanguineti, R.; Traverso, C.E.; Viviani, G.L.; Nicolo, M. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro. Eur. J. Ophthalmol. 2016, 26, 425–430.
41. Nishijima, K.; Ng, Y.S.; Zhong, L.C.; Bradley, J.; Schubert, W.; Jo, N.; Akita, J.; Samuelsson, S.J.; Robinson, G.S.; Adamis, A.P. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 2007, 171, 53–67.
42. Klettner, A.; Tahmaz, N.; Dithmer, M.; Richert, E.; Roider, J. Effects of aflibercept on primary RPE cells: Toxicity, wound healing, uptake and phagocytosis. Br. J. Ophthalmol. 2014, 98, 1448–1452.
43. Klettner, A.K.; Kruse, M.L.; Meyer, T.; Wesch, D.; Kabelitz, D.; Roider, J. Different properties of VEGFantagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247, 1601–1608.
44. Inan, U.U.; Avci, B.; Kusbeci, T.; Kaderli, B.; Avci, R.; Temel, S.G. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Investig. Ophthalmol. Vis. Sci. 2007, 48, 1773–1781.
45. Avci, B.; Avci, R.; Inan, U.U.; Kaderli, B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Investig. Ophthalmol. Vis. Sci. 2009, 50, 3438–3446.
46. Januschowski, K.; Schnichels, S.; Hagemann, U.; Koch, V.; Hofmann, J.; Spitzer, M.S.; Bartz-Schmidt, K.U.; Szurman, P.; Luke, M.; Aisenbrey, S. Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model. Acta Ophthalmol. 2014, 92, e305–e311.
47. Harada, T.; Harada, C.; Kohsaka, S.; Wada, E.; Yoshida, K.; Ohno, S.; Mamada, H.; Tanaka, K.; Parada, L.F.; Wada, K. Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J. Neurosci. 2002, 22, 9228–9236.
48. Hu, L.M.; Luo, Y.; Zhang, J.; Lei, X.; Shen, J.; Wu, Y.; Qin, M.; Unver, Y.B.; Zhong, Y.; Xu, G.T. et al. EPO reduces reactive gliosis and stimulates neurotrophin expression in Müller cells. Front. Biosci. 2011, 3, 1541–1555.
49. Fu, S.; Dong, S.; Zhu, M.; Sherry, D.M.; Wang, C.; You, Z.; Haigh, J.J.; Le, Y.Z. Müller glia are a major cellular source of survival signals for retinal neurons in diabetes. Diabetes 2015, 64, 3554–3563.
50. Unterlauft, J.D.; Claudepierre, T.; Schmidt, M.; Müller, K.; Yafai, Y.; Wiedemann, P.; Reichenbach, A.; Eichler, W. Enhanced survival of retinal ganglion cells is mediated by Müller glial cell-derived PEDF. Exp. Eye Res. 2014, 127, 206–214.
51. Gonzalez-Fernandez, F.; Landers, R.A.; Glazebrook, P.A.; Fong, S.L.; Liou, G.I.; Lam, D.M.; Bridges, C.D. An extracellular retinol-binding glycoprotein in the eyes of mutant rats with retinal dystrophy: Development, localization, and biosynthesis. J. Cell Biol. 1984, 99, 2092–2098.
52. Ishikawa, M.; Sawada, Y.; Yoshitomi, T. Structure and function of the interphotoreceptor matrix surrounding retinal photoreceptor cells. Exp. Eye Res. 2015, 133, 3–18.
53. den Hollander, A.I.; McGee, T.L.; Ziviello, C.; Banfi, S.; Dryja, T.P.; Gonzalez-Fernandez, F.; Ghosh, D.; Berson, E.L. A homozygous missense mutation in the IRBP gene (RBP3) associated with autosomal recessive retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 2009, 50, 1864–1872.
54. Sands, M.; Howell, K.; Costello, C.M.; McLoughlin, P. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir. Res. 2011, 12, 17.
55. Balaiya, S.; Ferguson, L.R.; Chalam, K.V. Evaluation of sirtuin role in neuroprotection of retinal ganglion cells in hypoxia. Investig. Ophthalmol. Vis. Sci. 2012, 53, 4315–4322.
56. Yang, C.; Lafleur, J.; Mwaikambo, B.R.; Zhu, T.; Gagnon, C.; Chemtob, S.; Di Polo, A.; Hardy, P. The role of lysophosphatidic acid receptor (LPA1) in the oxygen-induced retinal ganglion cell degeneration. Investig. Ophthalmol. Vis. Sci. 2009, 50, 1290–1298.
57. Yuan, Y.; Hilliard, G.; Ferguson, T.; Millhorn, D.E. Cobalt inhibits the interaction between hypoxiainducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-α. J. Biol. Chem. 2003, 278, 15911–15916.
58. Shen, W.; Li, S.; Chung, S.H.; Gillies, M.C. Retinal vascular changes after glial disruption in rats. J. Neurosci. Res. 2010, 88, 1485–1499.
59. Shen, W.; Zhang, J.; Chung, S.H.; Hu, Y.; Ma, Z.; Gillies, M.C. Submacular DL-α-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature. Investig. Ophthalmol. Vis. Sci. 2011, 52, 119–127.